Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord-derived mesenchymal stem cells (Shandong University)
- Development stage
- Unknown
- Lead developer
- Shandong University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) are a multipotent cell therapy candidate being investigated by Shandong University for the treatment of type 2 diabetes mellitus (T2DM). These cells, typically isolated from the Wharton's jelly of the umbilical cord, possess significant immunomodulatory, anti-inflammatory, and pro-regenerative properties. In the context of T2DM, hUC-MSCs are intended to improve glycemic control by reducing systemic inflammation and alleviating insulin resistance in peripheral tissues. They may also exert protective effects on pancreatic beta cells through the secretion of various paracrine factors, potentially preserving endogenous insulin production and slowing disease progression. Shandong University has advanced this therapy into Phase 1/2 clinical testing to evaluate its safety profile and impact on clinical markers such as HbA1c and C-peptide levels.
- Other names
- umbilical cord-derived mesenchymal stem cellsumbilical cord mesenchymal stem cellsWharton's jelly-derived mesenchymal stem cells
Beyond the preview
Go deeper on human umbilical cord-derived mesenchymal stem cells (Shandong University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord-derived mesenchymal stem cells (Shandong University).